# Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

> **NCT05969041** · PHASE1 · RECRUITING · sponsor: **Myeloid Therapeutics** · enrollment: 48 (estimated)

## Conditions studied

- Epithelial Tumors, Malignant

## Interventions

- **DRUG:** MT-302 (A)

## Key facts

- **NCT ID:** NCT05969041
- **Lead sponsor:** Myeloid Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-02
- **Primary completion:** 2027-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05969041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05969041, "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05969041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*